Pharmacology, Biochemistry and Behavior 76 (2003) 17 – 25
www.elsevier.com/locate/pharmbiochembeh
Functional role of exogenous administration of substance P in chronic
constriction injury model of neuropathic pain in gerbils
Theo F. Meerta,*, Kris Vissersb, Frank Geenena, Vesa K. Kontinenc
a
R&D, PRD Johnson&Johnson, Turnhoutseweg 30, B-2340 Beerse, Belgium
Multidisciplinary Pain Center, Ziekenhuis Oost-Limburg, ZOL, Schiepse Bos, B-3600 Genk, Belgium
c
Department of Pharmacology, Institute of Biomedicine, University of Helsinki, P.O. Box 8, Helsinki Fin 001400, Finland
b
Received 10 December 2002; received in revised form 29 May 2003; accepted 11 June 2003
Abstract
Substance P (SP) acts as a transmitter of nociception in both the peripheral and the central nervous system. Because the NK-1 receptors in
gerbils are comparable to those in humans, gerbil models could be used to study the role of SP in neuropathic pain. A modification of the rat
chronic constriction injury (CCI) model of neuropathic pain was produced in male gerbils by placing four loose chromic catgut ligatures
around the sciatic nerve. This procedure clearly resulted in mechanical hypersensitivity. Intraplantar injections of SP and the selective NK-1
receptor agonist, [Sar9-Met(O2)11]-substance P (Sar-SP), to the paw ipsilateral to the nerve injury and intrathecal administration of these
peptides produced paw-lifting behavior in the CCI gerbils in thermoneutral conditions. In sham-operated and nonoperated controls, no such
effects were observed. Systemic administration of the NK-1 antagonist R116301 attenuated the SP and the Sar-SP-induced paw-lifting
behavior in the CCI gerbils indicating the role of NK-1 receptors in these effects. Intraplantar injection of the highest dose of SP (200 ng) to
the paw contralateral to the CCI produced lifting of the paw ipsilateral to the injury, indicative for spinal mechanisms especially since
administration of SP to the ipsilateral front paw or even intracardially did not have any effect at all. The SP-induced responses were not
antagonized by the NMDA antagonist MK801. These results indicate that the peripheral and spinal SP reveal an increased reactivity in a
neuropathic pain model. This increased pain sensitivity seems to involve spinal NK-1 mechanisms.
D 2003 Elsevier Inc. All rights reserved.
Keywords: Neurokinins; NK-1 receptors; Allodynia; Neuropathic pain; Chronic constriction injury
1. Introduction
Substance P (SP) is a well-established transmitter of
nociception in both the peripheral and the central nervous
system and its role in nociceptive and inflammatory pain has
been studied extensively (Quartara and Maggi, 1998; Snijdelaar et al., 2000). In primary afferent nerves, SP is found
primarily in the small, unmyelinated neurons. In the chronic
constriction injury (CCI) model of neuropathic pain (Bennett and Xie, 1988), four loose chromic catgut ligatures are
placed around the rat sciatic nerve. Constriction and perineural inflammation lead to behavioral symptoms of neuropathic pain. In rats, the CCI model has been described to
lead to a loss of preferential large myelinated and unmyelinated fibers. (Carlton et al., 1991; Coggeshall et al., 1993;
* Corresponding author. Tel.: +32-14-60-32-14; fax: +32-14-60-59-44.
E-mail address: tmeert@prdbe.jnj.com (T.F. Meert).
0091-3057/$ – see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0091-3057(03)00187-4
Bai et al., 1999). It could be expected that the role of SP
would become more prominent in neuropathic pain states
where myelinated fibers are primarily affected, resulting in
an increase in the relative proportion of the remaining small
and unmyelinated fibers. However, the course of the hyperalgesia in the rat CCI model is not clearly related to the
proportion of large myelinated fibers in the affected nerve
(Coggeshall et al., 1993). SP-like immunoreactivity and
expression of preprotachykinin (PPT) mRNA in the dorsal
horn of the spinal cord decrease after nerve injury (Garrison
et al., 1993; Ghoul et al., 1993; Nahin et al., 1994; Xu et al.,
1996; Malmberg and Basbaum, 1998). This can be
explained at least in part by the nerve injury-induced loss
of small fibers containing SP and does not necessarily
reflect the situation in the remaining functional neurons.
Complex changes in PPT mRNA and SP levels in dorsal
root ganglion (DRG) neurons have been described after
nerve injury (Herzberg et al., 1994; Marchand et al., 1994;
Noguchi et al., 1994; Herzberg et al., 1996; Ma and Bisby,
18
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
1998; McLachlan and Hu, 1998). Furthermore, changes in
the effect of SP on the excitability of DRG neurons after
axotomy have also been described. Indeed, changes in the
SP levels in neuropathic conditions may be associated with
or even initiated by alterations in the release of the peptide,
in the NK-1 receptor expression (Malmberg and Basbaum,
1998), and in the functional coupling of the NK-receptors.
Furthermore, recently, the NK-1 antagonist L-732 138 was
demonstrated to overcome the CCI-induced tactile and cold
nociceptive changes in rat (Cahill and Coderre, 2002).
These data demonstrate that SP is involved both in the
induction and the maintenance of neuropathic pain and that
specifically NK-1 antagonists seem to play some role in
neuropathic pain. However, more data are needed to fully
understand these mechanisms.
Marked species differences have been described in the
pharmacology of the NK-1 receptors, necessitating the
development of pain models in species other than rats and
mice (Maggi, 1995) to fully evaluate the role of tachykinins
in neuropathic pain. Based on binding studies and pharmacological experiments, the gerbil NK-1 receptor is similar to
the human form (Beresford et al., 1991). Thus, gerbil
models could be used to study the effects of SP and
neurokinin receptor antagonists in neuropathic pain. In the
present study, the CCI model of neuropathic pain (Bennett
and Xie, 1988) has been adapted to gerbils. The aim of the
study was to validate the CCI model in gerbils and to assess
the effects of peripheral administration of SP in this model.
The effects of spinal administration of SP were studied to
find the mechanism of the allodynia-like behavior evoked
by peripherally administered SP. Furthermore, the role of
NK-1 receptors was evaluated testing the NK-1 agonist,
[Sar9-Met(O2)11]-substance P (Sar-SP), and the antagonist,
R116301 (Megens et al., 2002).
2. Materials and methods
2.1. Animals
The modification of the CCI model of neuropathic pain
(Bennett and Xie, 1988), described previously in rats, was
produced in adult male gerbils [Meriones unguiculatus,
Crl(MON)BR, Charles River Deutschland, Sulzfeld, Germany] weighing 60 –75 g at the beginning of the experiment.
The gerbils were housed individually in plastic cages under
artificial lighting with a fixed 12:12-h light – dark cycle. Food
and water were available ad libitum. Guidelines for animal
research by the International Association for the Study of
Pain (Zimmermann, 1983) were adhered to, and the study
was accepted by the Institutional Ethical Committee.
2.2. The nerve injury model
The animals were anaesthetized with pentobarbital (60
mg/kg body weight), the sciatic nerve was exposed, and four
loose chromic catgut ligatures (6/0 Chromic catgut, Ethicon,
Somerville, NJ, USA) placed around the sciatic nerve. A
sham operation was performed by exposing, but not ligating,
the sciatic nerve. After checking for hemostasis, the muscle,
the adjacent fascia, and the skin were closed with sutures.
2.3. Intrathecal catheterization
In a group of gerbils, after the CCI ligation, a PE-10
catheter was placed into the intrathecal space using the
lumbar approach, as described earlier in rats (Boersma et al.,
1992). To reduce the diameter of the catheter, 1 cm of the tip
was stretched to double the length using hot water.
The dorsal aspect of L3-L6 vertebrae were exposed by
skin incision and a small cut through the paravertebral
muscles. The spinal process of the L5 vertebra was carefully
removed, and the ligamentum flavum and the dura mater
were penetrated at the base of L4 vertebra with a metal
probe. The catheter was inserted 5 mm to the subarachnoideal space, parallel to the cord, and fixed with a drop of
Histoacryl (B. Braun Surgical, Melsungen, Germany) glue
and a suture. The wound was closed in layers. The extra
epidural part of the catheter was tunneled subcutaneous to
the neck of the animals. Approximately 3 cm of the catheter
was left externally and the tip of the catheter was closed by
melting.
2.4. The behavioral symptoms of neuropathic pain
Mechanical allodynia was assessed by placing the animals in cages with a metal mesh platform and touching the
plantar surface of the paw with a metal probe (tip diameter 1
mm) connected to a pressure transducer (Somedic Sales,
Hörby, Sweden) and increasing the force applied to the paw
until the animal withdrew the paw (Moller et al., 1998). The
animals were allowed to habituate to the testing chambers
for 30 min before the first measurement. The mean of three
consecutive readings on both hind limbs in each animal was
used for analysis.
For testing cold and heat allodynia, animals were placed
on metal plates in a transparent, circular Plexiglas cage with
diameter of 190 mm. The temperature of the cold ( 4 jC)
and the warm ( + 40 jC) plate was selected on the basis of a
preliminary trial comparing normal animals with CCI-ligated animals. For assessment of the spontaneous paw-lifting
behavior, a thermoneutral ( + 32 jC) (Klir et al., 1990) metal
plate covered with a soft paper tissue sheet was used.
The number of times that the animal lifted the left or the
right hind limb off the platform and the duration of the lifts
were separately recorded during a 5-min observation period.
Limb movements that were considered a part of the animals’
normal movement (walking) were not included in the
assessment.
Experiments in normal animals indicated that gerbils
have a lower threshold on cold stimulation as compared to
other rodents. The behavioral assessments were performed 1
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
day before the CCI operation and 1, 3, 6, 8, 10, 13, 15, 17,
20, 30, and 35 days after the operation. Mechanical allodynia was extended up to 70 days after the operation.
2.5. Behavior produced by administration of SP
In a separate series of experiments, the effect of intraplantar administration of SP, vehicle (PBS), and of the
selective NK-1 receptor agonist, Sar-SP, on paw-lifting
behavior on a neutral plate were assessed in different groups
of animals 7 – 11 days after the CCI operation. Dose
response curves for peptides were constructed after intraplantar injections. These injections were all into the ipsilateral-operated hind paw using a volume of 50 Al and a 25Gauge needle. Immediately after the injection, the animals
were placed in an observation cage and the number and
duration of paw lifts were recorded as described above.
The effect of intrathecal administration of different doses
of SP was studied in an additional experiment using the
same experimental conditions. The intrathecal injection
volume was 10 Al. Observers followed a standard procedure
for recording side effects and complications.
In order to evaluate the site of action of systemic SP,
different groups of animals were studied after injection of
200 ng in the forepaw, the contralateral hind paw, and
intracardially. For all these experiments, gerbils were only
used once in a period of 7– 14 days after surgery.
Additionally, to study the duration of the paw-lifting
behavior after repeated administration of SP during 5 –20
days of interval after the nerve injury, groups of gerbils were
consecutively challenged on different days with an intraplantar injection of 200 ng of SP into the ipsilateral paw.
Each animal was used between three and five times, with a
washout of at least 3 days between subsequent testing. The
experiments were performed as described above.
In separate experiments, the NK-1 antagonist R116301
in different doses of 0.16 – 10.0 mg/kg, and the NMDA
antagonist MK-801 in doses of 0.01– 0.63 mg/kg, were
administered intraperitoneally 60 min before the SP challenge in order to study the effect of blocking these receptors
on the SP-induced paw-lifting behavior. SP was then
administered intraplantarly (200 ng) in the ipsilateral-operated paw or intrathecally (40 ng), and the paw-lifting
behavior on the thermoneutral plate was assessed as in
the previous experiments.
2.6. Drugs
SP, Sar-SP, and MK-801 were obtained from Tocris
Cookson (Bristol, UK). R116301 was produced at PRD
J&J, Beerse (Challet et al., 2001; Megens et al., 2002).
2.7. Blinding
All the experiments are blinded according to our standard
procedures. Animals are recognized by a subcutaneous
19
implanted system, which is blinded for the technician
performing the behavioral testing. Different drugs and
dosages are administered in a randomized way, blinded
for the observer. The blinding code is only broken when
all data are collected.
2.8. Statistical analysis
Results are presented as mean F S.E.M. The Mann –
Whitney Test, with Bonferroni correction for multiple
comparisons where appropriate, was used for statistical
analysis. Two-tailed significance level was set at P < .05.
3. Results
The CCI model in gerbils produced mechanical allodynia
lasting over 55 days after the injury, as indicated by a
reduction in paw withdrawal threshold to mechanical stimulation in the paw ipsilateral to the injury, but not in the paw
contralateral to the injury or in either one of the paws of the
sham-operated control animals (Fig. 1).
The CCI gerbils did not show specific signs of cold or
heat allodynia. Similar paw-lifting behavior was observed
on a cold ( 4 jC), a warm ( + 40 jC), or a thermoneutral
( + 32 jC) plate (Fig. 2). On all three plates, the animals
lifted selectively the paw ipsilateral to the nerve injury. As
such, no distinction with regard to temperature could be
made, and therefore the paw-lifting behavior probably indicates mechanical allodynia or spontaneous pain that is not
related to the temperature of the platform per se. The shamoperated control animals did not show any of these behaviors.
Intraplantar injection of SP in the paw ipsilateral to the
nerve injury caused a dose-dependent increase in the pawlifting time in the CCI gerbils but not in sham-operated or
nonoperated controls (Fig. 3).
In a separate experiment, the effect of the site of the SP
administration was studied; the mean F S.E.M. lifting time
after injection of 200 ng of SP to the paw ipsilateral to the
injury was 87.7 F 11.6 s, whereas for a vehicle injection it
was 20.7 F 3.4 s (n = 15, P=.002). Injection of the same
dose of 200 ng of SP to the paw contralateral to the CCI also
produced a statistically significant increased lifting of the
injured limb (92.7 F 23 s for SP vs. 29.6 F 7.1 s for vehicle,
n = 15, P =.04). Administration of SP in the front paw
ipsilateral to the nerve injury (12.3 F 3.4 s for SP vs.
9.8 F 2.4 s for vehicle, n = 10, P =.7) or intracardially
(19.9 F 7.2 s for SP vs. 9.8 F 2.4 s for vehicle, n = 10,
P =.2) did not reveal an increased reactivity.
The SP injection-induced paw-lifting behavior on the
neutral plate was significantly stronger than the spontaneous
paw-lifting behavior. The sham-operated and nonoperated
controls did not show any paw-lifting behavior after intraplantar SP (50 –200 ng) challenge over time.
In order to assess the SP effect over time, animals were
repeatedly challenged with 200 ng SP at 5– 20 days after
20
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
force (g)
30
25
20
15
10
5
0
CCI
0
days
10
20
30
40
50
60
70
force (g)
30
Fig. 2. Paw-lifting behavior after CCI in gerbils. Mean F S.E.M., n = 20,
duration of spontaneous paw lifting over a 5-min observation period on the
cold (open triangles pointing down), neutral (filled circles), and warm
(open triangles pointing up) plates are presented over time after the nerve
injury.
25
20
15
paw lifting(s)
150
10
5
0
sham
0
days
10
20
30
40
50
60
70
Fig. 1. Time curve of mechanical allodynia after CCI in gerbils.
Mean F S.E.M. force required to induce paw withdrawal response in CCI
model of neuropathic pain (top panel, n = 20) and in sham-operated control
animals (lower panel, n = 15) in the paw ipsilateral to the injury (filled
squares) and in the contralateral paw (open diamonds) is plotted against
time after the nerve injury. Asterisk (*) indicates statistically significant
differences.
100
surgery. In all cases, a clear SP-induced lifting behavior of
the injected paw was observed over the whole measured
period. The amount of paw lifting was always larger than
these of the non-CCI controls (Fig. 4).
Also, with Sar-SP, a dose-dependent increase in paw
lifting of the operated paw was observed after the injections
into the ipsilateral paw (Fig. 3).
Systemic administration of the NK-1 antagonist R116301
dose-dependently antagonized the effect of an intraplantar
injection of SP (200 ng) (Fig. 5). Also, the paw-lifting
behavior induced by intraplantar injection of Sar-SP (400
ng) was significantly attenuated by pretreatment with a dose
of 10 mg/kg (Fig. 3). No side effects were reported.
Intrathecal administration of SP (2.5 –40 ng, Fig. 6,
top panel) produced a dose-dependent increase in lifting
of the paw ipsilateral to the peripheral nerve injury but
did not produce any pain-related behavior in sham-operated controls (data not shown). The paw-lifting behavior
50
dose (ng)
0
0
50
100
200
400
Fig. 3. Paw-lifting behavior induced by intraplantar injection of SP (open
squares) and Sar-SP (filled diamonds) in CCI gerbils. Mean F S.E.M.,
n = 8 – 10, duration of paw lifting during a 5-min observation period on a
neutral plate immediately after the injection is presented against the dose.
Asterisk (*) indicates statistically significant difference from the effect of
vehicle. Additionally, the mean paw-lifting time resulting from intraplantar
injections of Sar-SP (400 ng) after pretreatment with NK-1 antagonist
R116301 (10 mg kg 1 ip, administered 60 min before the intraplantar
injection) is shown (filled circles). Hash (#) indicates statistically significant
difference to the effect of Sar-SP alone.
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
21
Fig. 4. The mean duration of paw lifting ( F S.E.M., n = 8) induced by
intraplantar injection of SP (200 ng) (filled circles .) and vehicle (open
circles o) during a 5-min observation period on neutral plate is plotted
against time after the CCI nerve injury. In this experiment, the animals were
used repeatedly for 3 – 5 times with a washout of at least 3 days between the
injections. Asterisk (*) indicates statistically significant difference from the
control.
induced intrathecally by 40 ng SP was antagonized by
intraperitoneal administration of the NK-1 selective antagonist R116301 (Fig. 6, bottom panel).
In order to further evaluate the mechanism of the
selectivity of the SP-induced paw lifting in gerbils, an
antagonism study of the ipsilateral CCI paw was studied
using an intraperitoneal treatment with the NMDA antagonist, MK801, at different doses, ranging from 0.01 to 0.63
m/kg. No antagonism of the SP-induced paw lifting was
observed (data not shown). Higher doses of MK801 (up to
Fig. 6. The effect of intrathecal administration of SP on paw-lifting
behavior on a neutral plate in CCI gerbils (top panel) and reversal of the
effect of SP by NK-1 antagonist R116301 (bottom panel). Mean F S.E.M.,
n = 7 (open squares), duration of paw lifting during a 5-min observation
period on a neutral plate immediately after the intrathecal injection of SP,
and mean F S.E.M., n = 7 (filled circles), duration of paw lifting
immediately after the intrathecal injection of SP (40 ng it) following
pretreatment with different doses of R116301 administered intraperitoneally
60 min before the intrathecal injection is plotted against the dose. Asterisk
(*) indicates statistically significant difference from control.
10 mg/kg) have intrinsic motor effects and do not allow
further behavioral studies.
4. Discussion
Fig. 5. Attenuation of intraplantar SP-induced paw-lifting behavior by the
NK-1 antagonist R116301 (0.04 – 40 mg/kg ip, administered 60 min before
the intraplantar injection). Mean F S.E.M., n = 6, duration of paw lifting
during a 5-min observation period on a neutral plate is plotted against the
antagonist dose. Asterisk (*) indicates statistically significant difference
from the effect of vehicle.
The chronic constriction of the sciatic nerve in gerbils
demonstrates clear signs of neuropathic pain behavior
similar as seen in rats and described by Bennett and Xie
(1988). A clear mechanical allodynia was present (Fig. 1).
Whereas in the CCI model in rats, both cold and heat
allodynia have been described (Bennett and Xie, 1988; Attal
et al., 1990); no clear differentiations between temperatureinduced allodynic responses were observed in gerbils. The
initial increased paw lifting on the cold and warm plates
disappeared over time and no differences among the three
22
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
temperature conditions were seen in our animals. The lack
of thermal allodynia in gerbils could be related to the
adaptations in thermoregulation that enable survival of this
species in the extreme temperatures of a desert (Oufara et
al., 1987; Klir et al., 1990). In order to evaluate the role of
SP in the nociceptive changes following CCI, different
challenge tests were performed.
Local administration of SP intraplantar into the hind paw
of a CCI-affected hind limb induced an increased spontaneous paw lifting. This effect was dose dependent and
exceeded the effects seen with vehicle as well as the effects
seen after testing on cold or warm plates. Furthermore, the
SP-induced hyperreactivity remained present for more than
20 days after surgery, a period in which intrinsic paw lifting
due to CCI surgery, as well as paw lifting on the cold and
warm plates, disappeared (see Figs. 2– 4).
In order to further evaluate the functional site of action of
this SP effect, different other SP challenge tests were
performed. Injections of SP in the hind paw contralateral
to the CCI resulted in a similar degree of spontaneous paw
lifting as compared to the ipsilateral challenge. Because SP
challenges in the ipsilateral front paw and intracardially did
not result in an increased paw lifting, the SP-induced
reactivity after subplantar ipsi- and contralateral paw injections is most likely spinal cord mediated. In order to further
evaluate this, SP was injected spinally. Intrathecal injections
of SP also produced a dose-dependent increase in the paw
lifting of the CCI hind paw. The activity was comparable to
the subplantar injections but occurred at lower concentrations of SP. As a result, it can be concluded that spinal
mechanisms play a role in the SP-induced increased reactivity in CCI gerbils. Comparable data are described in rats
(Aanonsen et al., 1992).
In previous experiments in nonneuropathic rats, injections of SP (10 ng –10 Ag) into the plantar skin of the hind
paws have been shown to produce mechanical hyperalgesia (Nakamura-Craig and Smith, 1989). After repeated
administration of SP, the hyperalgesia was provoked with
significantly lower SP doses (0.5 –10 ng), suggesting a
facilitation of the response (Nakamura-Craig and Smith,
1989). Injection of SP (0.2 –20 Ag) in the rat hind paw has
also been reported to produce paw favoring, a response
where the animal is ‘‘resting the paw lightly on the floor
while sitting in rest position’’ 1– 8 min after the injection
(Hong and Abbott, 1994). Peripheral administration of 0.1
Ag of SP has been reported to produce mechanical
allodynia and hyperalgesia in rats, attenuated by local
pretreatment with the NK-1 antagonist CP99,994-1 (Carlton et al., 1996). However, injection of SP to the receptive
field of unmyelinated afferents produces only a weak
short-lasting response in half of the neurons (Fitzgerald
and Lynn, 1979) and a weak excitatory effect on some
canine testicular polymodal receptors in an in vitro preparation (Mizumura et al., 1987), and SP has failed to
activate or sensitize C-fibers significantly in other previous
experiments (Lembeck and Gamse, 1977; Cohen and Perl,
1990). SP seems to have a role in the sensitization of CCI
animals.
In order to further evaluate which tachykinin receptor
might be involved in the SP-induced increased intrinsic
nociceptive behavior in CCI gerbils, some additional pharmacological tests were performed.
First, it was demonstrated that Sar-SP produced comparable effects as SP in CCI gerbils when administered later in
the ligated hind paw and intrathecally. Sar-SP is an NK-1
selective agonist that in most assays is approximately
equipotent with SP and essentially inactive at both NK-2
and NK-3 receptors (Drapeau et al., 1987). The slightly
lower potency of Sar-SP as compared to SP in the present
study could indicate that a minor component of the pawlifting behavior is meditated via receptors other than NK-1,
or more likely, that components such as physicochemical
properties of the solution or distribution of the peptide in the
paw after the injection are different from that of SP.
Secondly, systemic administration of the centrally acting
NK-1 selective antagonist R116301 (Romerio et al., 1999;
Megens et al., 2002) dose-dependently attenuated the SPinduced paw lifting after intraplantar and intrathecal administration. This indicates that the SP-induced paw-lifting
behavior was triggered via NK-1 receptors. R116301 also
antagonized the Sar-SP-induced paw lifting in the CCI
animals, again stressing the role of NK-1 tachykinin receptors in this phenomenon.
In general, there are conflicting data with regard to NK1
receptors in neuropathic pain. Mechanical allodynia after
spinal nerve ligation injury is reduced in NK-1 receptor
knockout mice (Mansikka et al., 2000), indicating that NK-1
receptors have a role in its development or maintenance.
However, in another study, there were no differences between the NK-1 receptor knockout and the wild-type control
animals in mechanical or cold allodynia after partial sciatic
nerve ligation, suggesting that NK-1 receptors are not
essential for mechanical allodynia resulting from this type
of peripheral nerve injury in mice (Martinez-Caro and Laird,
2000). Several selective NK-1 receptor antagonists (Campbell et al., 1998; Coudore-Civiale et al., 1998; Gonzalez et
al., 2000) have been reported to attenuate mechanical and
thermal allodynia and hyperalgesia in rat and guinea pig
models of neuropathic pain. NK-1 receptors seem to be
involved in behavioral responses to high-intensity heat
stimuli (Mansikka et al., 1999), but thermal hyperalgesia
is not attenuated in NK-1 receptor knockout mice (Mansikka et al., 2000). Also in rats, a recent study using the
NK-1 antagonist L-732,138 confirmed the role of NK-1
antagonists in neuropathic pain (Cahill and Coderre, 2002).
In clinical studies, failures have been reported with
different NK-1 antagonists in neuropathic pain (Boyce and
Hill, 2000).
Alternatively, to direct NK-1 receptor activation on the
primary afferents, release of nociceptive transmitters (e.g.,
bradykinin, prostaglandin, and histamine) from nonneuronal
structures in the skin (e.g., blood vessels, mast cells)
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
activated by the SP injection via NK-1 receptors on these
structures could initiate the activation of the primary afferents in this model. This mechanism does not require the
presence of NK-1 receptors in the peripheral terminals of the
primary afferents. However, mast cell degranulation by SP
appears to be a non-receptor-dependent response (Maggi,
1997) and would not be likely to be attenuated by NK-1
antagonists. Thus, the effect of peripherally administered SP
in the present study could be explained either by direct
activation of NK-1 receptors on the primary afferent neurons or by indirect activation of the primary afferent neurons
via NK-1 receptor-mediated release of neurotransmitters
from nonneuronal cells in the skin.
However, changes in the expression of the endogenous
peptides do not seem to be sufficient to explain the
increased effect of exogenous SP. In experiments where
an immune challenge with keyhole limpet hemocyanin was
used to produce an increase in the concentration of SP
dialysate samples collected from the paw, the SP secretion
response was increased and prolonged in neuropathic
animals and the effect was reversed by the NK-1 receptor
antagonist L-703,606. This could indicate that the neuropathic animals exhibited increased delayed-type hypersensitivity responses mediated by NK-1 receptors (Herzberg et
al., 1994, 1996). Increased expression of NK-1 receptors on
the primary afferent after nerve injury could lead to
increased afferent barrage after the SP injection. This could
be sufficient to initiate the paw-lifting behavior in the
animals with nerve injury but not in normal control animals. Thus, increased response to the peripheral administration of SP at the level of the primary afferent neurons
could explain the increased response to SP in CCI gerbils.
Alternatively, nerve injury-induced central sensitization
could lead to a comparable situation without any changes
in the periphery.
In CCI gerbils, injection of SP to both the hind paw ipsiand contralateral to the injury triggered lifting of the paw
ipsilateral to the injury. SP injections to the forepaw
ipsilateral to the nerve injury or intracardial administration
of SP did not produce paw-lifting behavior. Hence, the
paw-lifting behavior seems to be mediated via a segmental
spinal mechanism triggered by the primary afferent activation. There is well-documented evidence for a variety of
changes in the contralateral nonlesioned side following
peripheral nerve injuries (Koltzenburg et al., 1999). In the
rat CCI model, behavioral symptoms of neuropathic pain
(Attal et al., 1994; Carlton et al., 1994) and neurochemical
changes in the spinal cord (Wagner et al., 1993; Behbehani
and Dollberg-Stolik, 1994; Hama et al., 1994) are frequently observed on the side contralateral to the injury, and
peripheral vascular reactivity to SP has been reported to
decrease bilaterally in CCI rats 2 –5 weeks after the injury
(Basile et al., 1993). Based on the findings of the present
study, it is not possible to define the neurochemical
mechanism of the paw-lifting behavior triggered by SP
injection to the contralateral paw in the CCI gerbils.
23
However, this can be interpreted as an indication that
central, probably spinal plastic, changes underlie this response rather than increased excitability of the primary
afferent neurons.
Intrathecal administration of SP (2.5 – 40 ng) produced
paw lifting in CCI gerbils in doses, which were lower than
those that triggered this behavior after intraplantar injections (50 – 200 ng). This effect was antagonized by
R116301, indicating an NK-1 receptor-mediated mechanism. In previous behavioral studies in normal rats, higher
concentrations of SP (100 ng– 20 Ag it) have been shown to
produce short-lasting mechanical (Matsumura et al., 1985)
and heat (Yasphal et al., 1982; Coderre and Melzack, 1991)
hyperalgesia. In rat microdialysis experiments, intrathecal
administration of SP leads to an increase in the spinal
release of the excitatory amino acids aspartate and glutamate into the cerebrospinal fluid, and experimental peripheral neuropathy decreased the dose of SP required to trigger
the excitatory amino acid release (Skilling et al., 1992).
Neonatal capsaicin pretreatment blocks this SP-induced
excitatory amino acid release in both neuropathic and
control animals (Skilling et al., 1992), indicating a Cfiber-mediated mechanism probably relevant to pain processing. However, in the present study, pretreatment with
NMDA-receptor antagonist MK-801 did not prevent the
SP-induced paw-lifting behavior, indicating that excitatory
amino acid activity mediated via NMDA receptors is not
mainly involved.
Other possible spinal mechanisms include increased
excitatory amino acid release mediated via postsynaptic
AMPA receptors, increased release of peptide transmitters,
including SP, the other neurokinins, and CGRP, and
presynaptic modulations. An increase of NK-1 receptorlike immunoreactivity in dorsal horn of the spinal cord has
been described in mice after partial ligation of the sciatic
nerve (Malmberg and Basbaum, 1998). Since spinally
administered SP triggered the paw-lifting behavior in
neuropathic gerbils, it might also act as an excitatory
transmitter at the spinal level mediating the paw-lifting
response induced by peripheral SP injections. Under normal conditions, spinally administered SP selectively enhances C-fiber-evoked activity without affecting A-fibermediated activity (Kellstein et al., 1990). However, nerve
injuries have been demonstrated to alter the expression
pattern of SP in the DRG, and therefore this does not
necessarily indicate a C-fiber-mediated mechanism in CCI
gerbils.
In conclusion, CCI of the sciatic nerve produces longterm mechanical allodynia in gerbils. Peripheral administration of SP in the hind paws of the CCI animals bilaterally
triggers paw-lifting behavior mediated via NK-1 receptors.
Intrathecal administration of SP in CCI gerbils also brings
about the same paw-lifting behavior. This behavior could be
due to increased release of excitatory transmitters, including
SP, in the spinal cord as a response to activation of the
primary afferents in the injured nerve.
24
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
References
Aanonsen LM, Kajander KC, Bennett GJ, Seybold VS. Autoradiographic
analysis of 125I-substance P binding in rat spinal cord following
chronic constriction injury of the sciatic nerve. Brain Res 1992;
596(1 – 2):259 – 68.
Attal N, Jazat F, Kayser V, Guilbaud G. Further evidence for ‘pain-related’
behaviours in a model of unilateral peripheral mononeuropathy. Pain
1990;41(2):235 – 51.
Attal N, Filliatreau G, Perrot S, Jazat F, Di Giamberardino L, Guilbaud G.
Behavioural pain-related disorders and contribution of the saphenous
nerve in crush and chronic constriction injury of the rat sciatic nerve.
Pain 1994;59(2):301 – 12.
Bai YH, Takemitsu M, Atsuta Y, Matsuno T. Peripheral mononeuropathy
induced by loose ligation of the sciatic nerve in the rat: behavioral,
electrophysiological and histopathologic studies. Exp Anim 1999;
48(2):87 – 94.
Basile S, Khalil Z, Helme RD. Skin vascular reactivity to the neuropeptide
substance P in rats with peripheral mononeuropathy. Pain 1993;
52(2):217 – 22.
Behbehani MM, Dollberg-Stolik O. Partial sciatic nerve ligation results in
an enlargement of the receptive field and enhancement of the response
of dorsal horn neurons to noxious stimulation by an adenosine agonist.
Pain 1994;58:421 – 8.
Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces
disorders of pain sensation like those seen in man. Pain 1988;33(1):
87 – 107.
Beresford IJ, Birch PJ, Hagan RM, Ireland SJ. Investigation into species
variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 1991;104(2):292 – 3.
Boersma FP, Meert TF, Vercauteren M. Spinal sufentanil in rats: Part I.
Epidural versus intrathecal sufentanil and morphine. Acta Anaesthesiol
Scand 1992;36(2):187 – 92.
Boyce S, Hill RG. In: Devor M, Rowbotham MC, Wiesenfeld-Hallin Z,
editors. Proceedings of the 9th World Congress on Pain. Seattle: IASP
Press; 2000. p. 313 – 24.
Cahill CM, Coderre TJ. Attenuation of hyperalgesia in a rat model of
neuropathic pain after intrathecal pre- or post-treatment with a neurokinin-1 antagonist. Pain 2002;95(3):277 – 85.
Campbell EA, Gentry CT, Patel S, Panesar MS, Walpole CS, Urban L.
Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a
model of neuropathic pain in the guinea-pig. Neuroscience 1998;87(3):
527 – 32.
Carlton SM, Dougherty PM, Pover CM, Coggeshall RE. Neuroma formation and numbers of axons in a rat model of experimental peripheral
neuropathy. Neurosci Lett 1991;131(1):88 – 92.
Carlton SM, Lekan HA, Kim SH, Chung JM. Behavioral manifestations of
an experimental model for peripheral neuropathy produced by spinal
nerve ligation in the primate. Pain 1994;56(2):155 – 66.
Carlton SM, Zhou S, Coggeshall RE. Localization and activation of substance P receptors in unmyelinated axons of rat glabrous skin. Brain Res
1996;734:103 – 8.
Challet E, Dugovic C, Turek FW, Olivier Van R. The selective neurokinin 1
receptor antagonist R116301 modulates photic responses of the hamster
circadian system. Neuropharmacology 2001;40(3):408 – 15.
Coderre TJ, Melzack R. Central neural mediators of secondary hyperalgesia
following heat injury in rats: neuropeptides and excitatory amino acids.
Neurosci Lett 1991;131(1):71 – 4.
Coggeshall RE, Dougherty PM, Pover CM, Carlton SM. Is large myelinated fiber loss associated with hyperalgesia in a model of experimental
peripheral neuropathy in the rat? Pain 1993;52(2):233 – 42.
Cohen RH, Perl ER. Contributions of arachidonic acid derivatives and
substance P to the sensitization of cutaneous nociceptors. J Neurophysiol 1990;64(2):457 – 64.
Coudore-Civiale MA, Courteix C, Eschalier A, Fialip J. Effect of tachykinin receptor antagonists in experimental neuropathic pain. Eur J Pharmacol 1998;361(2 – 3):175 – 84.
Drapeau G, D’Orleans-Juste P, Dion S, Rhaleb NE, Rouissi NE, Regoli D.
Selective agonists for substance P and neurokinin receptors. Neuropeptides 1987;10(1):43 – 54.
Fitzgerald M, Lynn B. The weak excitation of some cutaneous receptors in
cats and rabbits by synthetic substance P. [proceedings]. J Physiol
(London) 1979;293:66P – 7P.
Garrison CJ, Dougherty PM, Carlton SM. Quantitative analysis of substance P and calcitonin gene-related peptide immunohistochemical
staining in the dorsal horn of neuropathic MK-801-treated rats. Brain
Res 1993;607(1 – 2):205 – 14.
Ghoul W, Volsi GL, Weinberg RJ, Rustioni A. Glutamate immunocytochemistry in the dorsal horn after injury or stimulation of the sciatic
nerve of rats. Brain Res Bull 1993;30(3 – 4):453 – 9.
Gonzalez MI, Field MJ, Hughes J, Singh L. Evaluation of selective NK(1)
receptor antagonist CI-1021 in animal models of inflammatory and
neuropathic pain. J Pharmacol Exp Ther 2000;294(2):444 – 50.
Hama AT, Sagen J, Pappas GD. Morphological characterization of dorsal
horn spinal neurons in rats with unilateral constriction nerve injury: a
preliminary study. Neurol Res 1994;16(4):297 – 304.
Herzberg U, Murtaugh M, Beitz AJ. Chronic pain and immunity: mononeuropathy alters immune responses in rats. Pain 1994;59(2):219 – 25.
Herzberg U, Brown DR, Mullett MA, Beitz AJ. Increased delayed type
hypersensitivity in rats subjected to unilateral mononeuropathy is
mediated by neurokinin-1 receptors. J Neuroimmunol 1996;65(2):
119 – 24.
Hong Y, Abbott FV. Behavioural effects of intraplantar injection of inflammatory mediators in the rat. Neuroscience 1994;63(3):827 – 36.
Kellstein DE, Price DD, Hayes RL, Mayer DJ. Evidence that substance P
selectively modulates C-fiber-evoked discharges of dorsal horn nociceptive neurons. Brain Res 1990;526(2):291 – 8.
Klir JJ, Heath JE, Bennani N. An infrared thermographic study of surface
temperature in relation to external thermal stress in the Mongolian
gerbil, Meriones unguiculatus. Comp Biochem Physiol, A 1990;
96(1):141 – 6.
Koltzenburg M, Wall PD, McMahon SB. Does the right side know what the
left is doing? Trends Neurosci 1999;22(3):122 – 7.
Lembeck F, Gamse R. Lack of algesic effect of substance P on paravascular
pain receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 1977;299(3):
295 – 303.
Ma W, Bisby MA. Increase of preprotachykinin mRNA and substance P
immunoreactivity in spared dorsal root ganglion neurons following
partial sciatic nerve injury. Eur J Neurosci 1998;10(7):2388 – 99.
Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;
26(5):911 – 44.
Maggi CA. The effects of tachykinins on inflammatory and immune cells.
Regulatory Pept 1997;70(2 – 3):75 – 90.
Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a
model of neuropathic pain: behavioral and neuroanatomical correlates.
Pain 1998;76(1 – 2):215 – 22.
Mansikka H, Shiotani M, Winchurch R, Raja SN. Neurokinin-1 receptors
are involved in behavioral responses to high-intensity heat stimuli and
capsaicin-induced hyperalgesia in mice. Anesthesiology 1999;90(6):
1643 – 9.
Mansikka H, Sheth RN, DeVries C, Lee H, Winchurch R, Raja SN. Nerve
injury-induced mechanical but not thermal hyperalgesia is attenuated in
neurokinin-1 receptor knockout mice. Exp Neurol 2000;162(2):343 – 9.
Marchand JE, Wurm WH, Kato T, Kream RM. Altered tachykinin expression by dorsal root ganglion neurons in a rat model of neuropathic pain.
Pain 1994;58(2):219 – 31.
Martinez-Caro L, Laird JM. Allodynia and hyperalgesia evoked by sciatic
mononeuropathy in NKI receptor knockout mice. NeuroReport 2000;
11(6):1213 – 7.
Matsumura H, Sakurada T, Hara A, Sakurada S, Kisara K. Characterization
of the hyperalgesic effect induced by intrathecal injection of substance
P. Neuropharmacology 1985;24(5):421 – 6.
McLachlan EM, Hu P. Axonal sprouts containing calcitonin gene-related
peptide and substance P form pericellular baskets around large diameter
T.F. Meert et al. / Pharmacology, Biochemistry and Behavior 76 (2003) 17–25
neurons after sciatic nerve transection in the rat. Neuroscience 1998;
84(4):961 – 5.
Megens AA, Ashton D, Vermeire JC, Vermote PC, Hens KA, Hillen LC, et al.
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piper idinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally
active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther 2002;
302(2):696 – 709.
Mizumura K, Sato J, Kumazawa T. Effects of prostaglandins and other
putative chemical intermediaries on the activity of canine testicular
polymodal receptors studied in vitro. Pflügers Arch 1987;408(6):
565 – 72.
Moller KA, Johansson B, Berge OG. Assessing mechanical allodynia in the
rat paw with a new electronic algometer. J Neurosci Methods 1998;
84(1 – 2):41 – 7.
Nahin RL, Ren K, De Leon M, Ruda M. Primary sensory neurons exhibit
altered gene expression in a rat model of neuropathic pain. Pain
1994;58(1):95 – 108.
Nakamura-Craig M, Smith TW. Substance P and peripheral inflammatory
hyperalgesia. Pain 1989;38(1):91 – 8.
Noguchi K, Dubner R, De Leon M, Senba E, Ruda MA. Axotomy induces
preprotachykinin gene expression in a subpopulation of dorsal root
ganglion neurons. J Neurosci Res 1994;37(5):596 – 603.
Oufara S, Barre H, Rouanet JL, Chatonnet J. Adaptation to extreme ambient
25
temperatures in cold-acclimated gerbils and mice. Am J Physiol 1987;
253(1 Pt 2):R39 – 45.
Quartara L, Maggi CA. The tachykinin NK1 receptor: Part II. Distribution
and pathophysiological roles. Neuropeptides 1998;32(1):1 – 49.
Romerio SC, Linder L, Haefeli WE. Neurokinin-1 receptor antagonist
R116301 inhibits substance P-induced venodilation. Clin Pharmacol
Ther 1999;66(5):522 – 7.
Skilling SR, Harkness DH, Larson AA. Experimental peripheral neuropathy
decreases the dose of substance P required to increase excitatory amino
acid release in the CSF of the rat spinal cord. Neurosci Lett 1992;
139(1):92 – 6.
Snijdelaar DG, Dirksen R, Slappendel R, Crul BJ. Substance P. Eur J Pain
2000;4(2):121 – 35.
Wagner R, DeLeo JA, Coombs DW, Willenbring S, Fromm C. Spinal
dynorphin immunoreactivity increases bilaterally in a neuropathic pain
model. Brain Res 1993;629(2):323 – 6.
Xu J, Pollock CH, Kajander KC. Chromic gut suture reduces calcitoningene-related peptide and substance P levels in the spinal cord following
chronic constriction injury in the rat. Pain 1996;64(3):503 – 9.
Yasphal K, Wright DM, Henry JL. Substance P reduces tail-flick latency:
implications for chronic pain syndromes. Pain 1982;14(2):155 – 67.
Zimmermann M. Ethical guidelines for investigation of experimental pain
in conscious animals. Pain 1983;16:109 – 10.